S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
NYSE:STE

STERIS (STE) Stock Price, News & Analysis

$224.49
-1.03 (-0.46%)
(As of 01:08 PM ET)
Today's Range
$224.35
$226.57
50-Day Range
$214.85
$236.03
52-Week Range
$180.54
$254.00
Volume
81,207 shs
Average Volume
417,671 shs
Market Capitalization
$22.18 billion
P/E Ratio
39.32
Dividend Yield
0.93%
Price Target
$239.60

STERIS MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
6.2% Upside
$239.60 Price Target
Short Interest
Bearish
2.66% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.07mentions of STERIS in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.80%
From $8.67 to $9.52 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.24 out of 5 stars

Medical Sector

161st out of 939 stocks

Surgical Appliances & Supplies Industry

7th out of 18 stocks

STE stock logo

About STERIS Stock (NYSE:STE)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STE Stock Price History

STE Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
STE Mar 2024 190.000 call
Why Steris (STE) is a Top Growth Stock for the Long-Term
What 4 Analyst Ratings Have To Say About Steris
STERIS plc (NYSE:STE) Q3 2024 Earnings Call Transcript
Recap: Steris Q3 Earnings
Steris: Fiscal Q3 Earnings Snapshot
STERIS plc Q3 Profit Increases, beats estimates
Steris (STE) Q3 Earnings and Revenues Top Estimates
See More Headlines
Receive STE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Ex-Dividend for 3/22 Dividend
2/22/2024
Dividend Payable
3/22/2024
Today
3/28/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
85915210
Employees
17,100
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$239.60
High Stock Price Target
$265.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+6.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$107.03 million
Pretax Margin
12.62%

Debt

Sales & Book Value

Annual Sales
$4.96 billion
Cash Flow
$19.21 per share
Book Value
$61.31 per share

Miscellaneous

Free Float
97,875,000
Market Cap
$22.28 billion
Optionable
Optionable
Beta
0.80

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy STERIS Stock? STE Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of STERIS was last updated on Tuesday, March 26, 2024 at 12:06 AM.

Pros

Here are some ways that investors could benefit from investing in STERIS plc:

  • STERIS plc has shown consistent revenue growth, with a 14.8% increase in revenue on a year-over-year basis.
  • Recent earnings report exceeded analyst estimates, with $2.22 earnings per share for the quarter, beating the consensus estimate by $0.05.
  • Strong return on equity of 13.67% indicates efficient use of shareholder funds.
  • STERIS plc has a diverse institutional investor base, with significant stakes held by reputable firms like Vanguard Group Inc. and BlackRock Inc.
  • Despite recent fluctuations, STERIS plc has a stable market cap of $23.00 billion, providing a solid foundation for investment.

Cons

Investors should be bearish about investing in STERIS plc for these reasons:

  • The stock price of STERIS plc has experienced volatility, with recent trading down by 3.7% to $220.45, indicating potential market uncertainty.
  • Debt-to-equity ratio of 0.50 may raise concerns about the company's leverage and financial risk.
  • While revenue growth has been positive, STERIS plc's PE ratio of 40.93 may suggest the stock is currently overvalued.
  • Market analysts forecast earnings per share of 8.67 for the current fiscal year, which may not meet some investors' growth expectations.
  • Ownership concentration by institutional investors, with 94.69% of the stock currently held by such entities, could limit individual investor influence.

STE Stock Analysis - Frequently Asked Questions

Should I buy or sell STERIS stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STE shares.
View STE analyst ratings
or view top-rated stocks.

What is STERIS's stock price target for 2024?

5 brokers have issued twelve-month price targets for STERIS's shares. Their STE share price targets range from $215.00 to $265.00. On average, they predict the company's share price to reach $239.60 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for STE
or view top-rated stocks among Wall Street analysts.

How have STE shares performed in 2024?

STERIS's stock was trading at $219.85 at the beginning of 2024. Since then, STE shares have increased by 2.6% and is now trading at $225.52.
View the best growth stocks for 2024 here
.

When is STERIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our STE earnings forecast
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) released its quarterly earnings results on Wednesday, February, 7th. The medical equipment provider reported $2.22 earnings per share for the quarter, beating analysts' consensus estimates of $2.17 by $0.05. The medical equipment provider earned $1.40 billion during the quarter, compared to analyst estimates of $1.35 billion. STERIS had a net margin of 10.48% and a trailing twelve-month return on equity of 13.67%. STERIS's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.02 earnings per share.
Read the conference call transcript
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Tuesday, January 30th. Stockholders of record on Friday, February 23rd will be paid a dividend of $0.52 per share on Friday, March 22nd. This represents a $2.08 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, February 22nd.
Read our dividend analysis for STE
.

Is STERIS a good dividend stock?

STERIS (NYSE:STE) pays an annual dividend of $2.08 per share and currently has a dividend yield of 0.94%. The company has been increasing its dividend for 19 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 36.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STE will have a dividend payout ratio of 21.85% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for STE.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided earnings per share guidance of 8.600-8.700 for the period, compared to the consensus EPS estimate of 8.670. The company issued revenue guidance of $5.5 billion-$5.5 billion, compared to the consensus revenue estimate of $5.4 billion.

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

Who are STERIS's major shareholders?

STERIS's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.01%), Vanguard Group Inc. (12.01%), Massachusetts Financial Services Co. MA (5.88%), WCM Investment Management LLC (4.91%), Price T Rowe Associates Inc. MD (1.64%) and Northern Trust Corp (1.18%). Insiders that own company stock include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi and Renato Tamaro.
View institutional ownership trends
.

How do I buy shares of STERIS?

Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:STE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners